In the present post hoc analysis published in Diabetes Care , Klein and colleagues examined data on the 16 996 adults participating in four large randomised, double-blind, placebo-controlled clinical trials assessing the safety and efficacy of GLP-1 RAs: the LEADER trial of liraglutide, the STEP 2 and SUSTAIN 6 trials of subcutaneous semaglutide, and the PIONEER 6 trial of oral semaglutide
that is, to examine whether absolute rather than relative differences in hazard could be found ( Sensitivity and subgroup analyses Several sensitivity and subgroup analyses were performed
Directly acts as an alpha-2 adrenergic antagonist, elevating blood flow, increasing the release of fat through lipolysis, and stimulating the nervous system for a higher metabolism
These mouse studies appear relevant to human disease, as a large number of studies have shown that polymorphisms in PON1 are associated with increased risk for atherosclerosis (265)